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PEX12 Novel Mutation: A Case Report on 
Iranian Girl with Childhood Onset Peroxisomal 
Disorder: Pseudo ALD?
Introduction
Peroxisomal Biogenesis Disorders (PBDs) are peroxisomal 
disorders presenting as a clinical continuum consists of at 
least three phenotypes; Zellweger Syndrome (ZS), Neonatal 
adrenoleukodystrophy (NALD) and Infantile Refsum Disease (IRD) 
with ZS being the most and IRD the least severe presentation. The 
PEX genes, which encode proteins called peroxins, are involved in 
ZSDs pathogenesis. Type of mutation and dysfunction of affected 
peroxins will determine disease severity and clinical phenotype. 
Mutations in PEX1 are the most common cause of ZSD and account 
for 70% of the cases. PEX6 and PEX12 mutations comprise 16% and 
9%, as the second and third common causes of ZSDs, respectively 
[1].
We present a female patient with a new mutation in PEX12 
gene, and her clinical, biochemical assay and neuro imaging will be 
discussed. Ethical approval for this study was obtained by Pediatric 
neurology Research Center of Shahid Beheshti University of Medical 
sciences (SBMU).
Case Report
A seven-year old girl was referred to Pediatric Neurology 
Department of Mofid Children Hospital, Tehran, Iran, for regression 
in all neuro developmental milestones. She was delivered by an 
uneventful cesarean section at full term from consanguineous 
healthy parents of Turkish decent. There was no history of 
neonatal jaundice, however; she was admitted for 2 days because 
of restlessness. There was no history of feeding difficulty and her 
growth rate was within the normal range. She began walking at 
17 months old and talking on time and appropriately (parental 
report). Her parents didn’t notice any issues up to her fifth birthday 
when she started having slowly progressive appendicular and 
truncal ataxia. Dysarthria presented shortly after the ataxia, and 
her cognition gradually declined.
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Abstract
Objective: To report a 7 years old girl with genetic and biochemical characteristics of zellweger spectrum disorder who presented with phenotype 
and neuro imaging findings of adrenoleukodystrophy. 
Methods: Target gene sequencing was performed by using a custom designed panel for this patient with focused mutation analysis on 16 
peroxisomal genes included in the panel. Sanger sequencing was used to confirm the identified mutation. 
Results: This patient was homozygote for a missense mutation in exon 2 of the PEX 12 gene; c.541T>G (p.Tyr181Asp) which is a conserved residue 
in the N-terminal region crucial for localization to peroxisomes. Her parents and healthy sister were also found to have the same heterozygote mutation.
Conclusion: We suggest that PEX 12 gene mutations with a milder phenotype may be a potential candidate for posterior dominant leukodystrophy 
of childhood resembling X-linked ALD. This is entitled to pseudo- ALD and may be a diagnostic possibility in patients who develop ALD phenotype and 
neuroimaging particularly, in girls.
Keywords: Zellweger spectrum disorder; Childhood onset; Pseudo-ALD; PEX 12 gene; Novel mutation
Abbreviations: PBD: Peroxisomal Biogenesis Disorders; ZS: Zellweger Syndrome; NALD: Neonatal Adrenoleukodystrophy; IRD: Infantile Refsum 
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At the age of 6, she was unable to walk with speech ability 
limited to 1-2 words. Swallowing difficulties was followed at the 
age of 6.5. Her parents were first cousins. Her family history was 
positive for two cases of mental retardation and seizure disorder 
in addition to one death due to an unknown neurodegenerative 
disease. On examination, there were no dysmorphic features or 
organomegaly. Her neurological examination revealed spasticity in 
upper and lower extremities, and exaggerated deep tendon reflexes 
in the bedridden girl. The Ophthalmologic report was normal 
without any cataract or retinopathy, although she didn’t have 
proper fix and follow. Auditory Brain Stem response confirmed 
severe bilateral sensor neural hearing loss. All Liver enzymes and function, electrolytes, kidney, adrenal and thyroid tests 
returned normal. Abdominal ultrasound, echocardiography, nerve 
conduction velocity and electromyography were also reported in 
normal range.
Figure 1: MR T2 images show corticospianl tracts 
involvement that spare cerebellum (Upper row), hyper 
intensities in posterior white matter with different zones 
characteristic for ALD. (Lower row) 
MRI at the age of 5 revealed severe signal changes in per 
ventricular white matter of bilateral posterior occipital regions. 
There was no neocortical dysplasia or atrophy, and the cerebellum 
was normal. However, splenuim of corpus collosom and 
corticospinal tracts were affected (Figure 1). Different zones (ALD-
like) were clearly differentiated on T2 MR Image. Second MRI at the 
age of 7 revealed extensive white matter involvement along with 
generalized atrophy. MRS demonstrated a choline rise in respect 
to NAA (N-Acetyl Aspartic Acid) compatible with leukodystrophy 
pattern. 
Table 1: Summary of biochemical assay of the patient.
Metabolite (Plasma) Result Reference
Hexacosanoic acid 
(C-26)
4.5 nm/ml 0.2-1.6Tetracosahexaenoic 
acid(C-24)
122.4 nm/ml 12.0-94.0
Docosanoic acid 
(C-22)
41.8 nm/ml 15.0-113.0
C24/C22 2.99 0.55-1.05
C26/C22 0.109 0.005-0.029Phytanic acid 235.8 nm/ml 0.3-31.0Pristanic acid 118.9 nm/ml 0.0-3.0
Plasma ammonia, lactate and pyruvate were within 
normal range. Biochemical assay ruled out MLD and Krabbe 
with normal galactocerebrosidase and arylsulfatase A assay. 
ß-glucocerebrosidase assay, urine organic acid and plasma amino 
acid (HPLC) were normal, and celiac tests were negative. VLCFA 
assay showed a pattern observed in ZDSs; elevation of C26, Phytanic 
Acid and Pristatic acid in plasma, and increased C24/C22 and C26/
C22 ratios. These tests were sent to the Wagner stibbe referral 
laboratory in Gottingen/Germany and repeated twice (Table 1).
Genetic Study
The Germline DNA of the patient, her healthy sister and parents 
were extracted from white blood cells by salting out method. Target 
gene sequencing was performed by using a custom designed panel 
for this patient with focused mutation analysis on 16 peroxisomal 
genes included in the panel. In order to remove the common and 
benign variants, filtering steps were performed on the detected 
variants (MAF>1% in public database). Benign synonymous and 
missense variants were predicted by the bioinformatics prediction 
software (Mutation taster, PolyPhen2 and SIFT). All identified 
mutations were confirmed by Sanger sequencing. 
Figure 2: Pedigree and chromatograms which shows the 
mentioned mutation
The genetic testing confirmed that our patient is homozygote 
for a mutation defined as c.541T>G (p.Tyr181Asp) in exon 2 of 
PEX12 gene (NM-000286.2) which affects a conserved residue 
in the N-terminal region crucial for localization to peroxisomes. 
Clearly, the tyrosine residue in this position belongs to a polar class 
while aspartate is a charged (negative) amino acid. According to 
the software predictions, this mutation would not be tolerated in 
protein structure. Co-segregation of this variant has confirmed that 
our patients’ parents and healthy sister are heterozygous for this 
variant (Figure 2).
To our knowledge, this variant has not been reported before; 
however, Steinberg et al. had reported a frame shift mutation at 
the same position of the protein (Tyr181Leufs*37) in two different 
studies in 2004 and 2009 causing Peroxisome biogenesis disorders 
[1].
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Discussion
PEX12 gene mutations may present with milder phenotypes. 
However, we presented a novel mutation in PEX 12 gene with 
progressive leukodystrophy starting at the age of 5- year without 
any other organ involvement usually expected from ZSDs. She 
survived up to 8 years of age. The frame shift mutation of PEX12 
in the same position as hers (541_542 insT) is reported as 
heterozygote allele of ZS phenotype in at least two studies [1] but 
her missense mutation demonstrates X-ALD phenotype which is a 
single enzyme/protein deficiency disorder.
Historically, two other single peroxisomal enzyme deficiency 
including peroxisomal acyl-CoA oxidase1 deficiency (in 1998) and 
D-bifunctional protein deficiency (in 1987) were first described as 
pseudo-neonatal adrenoleukodystrophy and pseudo-ZD (recently 
named ZD-like disease) respectively, because of the similar sign and 
symptoms yet different pathogenesis [2]. Besides, it was previously 
noticed that male patients with late onset ZSD may be theoretically 
misdiagnosed as X-ALD. The reported patients however, had mostly 
PEX1 or PEX6 mutations or no genetic study had been done for 
them [3]. We didn’t find any report of PEX 12 mutations to have 
both ALD phenotype and Neuro imaging that might show the rarity 
or under diagnosed cases. PEX gene mutations may occur in some particular ethnic backgrounds and therefore not attract enough 
attention. Moreover, complex PEX12 interac tions with other PEX 
proteins may affect the diagnostic procedure. For instances, one 
study showed that over expression of either PEX5 or PEX 10 can 
suppress S320F mutation in PEX 12 [4]. 
Previous reported phenotypes associated with PEX12 
mutations include ZS, NALD, IRD presenting in different age 
range and severity, SMA-like disorder [4], and ZD with severe 
mitochondrial myopathy [5]. These  similarities and “pseudo 
concepts” may suggest a common process that can be translated to 
a general therapeutic strategy.
In our report however, we were not able to perform ERG, 
ruling out possible asymptomatic retinal involvement, neither VEP nor skeletal survey given our patient clinical condition and non-
diagnostic nature of these assessments. We didn’t also perform the 
functional study; it may uncover some new aspects of PEX12 gene 
function.
Conclusion
 We suggest that PEX12 gene mutations could be a potential 
candidate in posterior dominant leukodystrophy resembling 
X-ALD. This is entitled to pseudo- ALD and may be a diagnostic 
possibility in patients who develop ALD phenotype and Neuro 
imaging particularly, in girls. Further studies are required for better 
identification of PEX12 mutations, genotype- phenotype coloration 
and its significance in leukodystrophy of childhood.
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